Ryboquin Raises £1.3m for Cancer Drug Development

A Scottish Borders-based pharmaceutical firm, Ryboquin has raised £1.3m towards cancer gene therapy drug development. The money will allow Ryboquin Ltd to take the product – named Ryboquin ECP-102 – one step closer to clinical trials. The firm, which has its headquarters in Selkirk, raised £800,000 from investors plus nearly £500,000 in a Scottish Enterprise

Continue Reading

J+J Announce Collaboration to Create Personalised Healthcare Solutions with 3D Printing

Today Johnson & Johnson announced a collaboration between Johnson & Johnson Services, Inc. and a subsidiary of HP Inc. The partnership will be focused on using 3D printing technologies to create better healthcare outcomes at a reduced cost. By working together, the companies plan to combine their scientific, clinical, material science and technological expertise to

Continue Reading

Pfizer to Test Cancer Immunotherapy Combination

Pfizer is reportedly gearing up to test a combination of three cancer drugs in human trials next year. According to the Financial Times, the trial, which will be one of the first to test a trio of immunotherapies, will monitor the safety and efficacy of the combination in patients with solid cancers. Although current immunotherapies

Continue Reading

Are You Paid Enough?

In our 2016 Life Science Salary Survey, we have discovered that a staggering 49% of UK Pharmaceutical Physicians believe that their salary does not reflect their current career level. Although the majority believed otherwise, it still shows significant discord and lack of confidence in salaries within the Life Science industry. Whatever the change in career,

Continue Reading

NHS England to fund HIV treatment Rezolsta

NHS England will provide crucial funding for Janssen’s once-daily, fixed-dose combination of darunavir and the pharmacoenhancer, cobicistat, called Rezolsta. Rezolsta is indicated for use in combination with other antiretroviral medications for treating adults with HIV-1, whose virus does not carry darunavir resistance-associated mutations. Meaning clinicians across England will be able to routinely prescribe darunavir –

Continue Reading